Showing 3021-3030 of 3039 results for "".
- EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-arvo-annual-meeting/2480232/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophtha
- American Academy of Optometry 2018 San Antonio Education Program Announcedhttps://modernod.com/news/american-academy-of-optometry-2018-san-antonio-education-program-announced/2480235/The American Academy of Optometry is pleased to announce highlights of the education program taking place at Academy 2018 San Antonio, November 7-10, 2018. The annual meeting offers a wide array of clinically relevant CE courses and cutting-edge research in the clinical and vision sciences. Atten
- Shire Announces Sale of Oncology Business to Servier for $2.4 Billionhttps://modernod.com/news/shire-announces-sale-of-oncology-business-to-servier-for-2-4-billion/2480237/Shire announced that it has entered into a definitive agreement with privately held French pharmaceutical group Servier S.A.S. to sell its Oncology business for $2.4 billion. “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Genetically Modified Cornea Safely and Effectively Prevents Rejection Post-Transplantationhttps://modernod.com/news/genetically-modified-cornea-safely-and-effectively-prevents-rejection-post-transplantation/2480247/Researchers engineered a donor cornea, introducing two genes intended to prevent new blood vessel formation following transplantation, and have shown this novel approach to be safe, well tolerated, and effective at reducing the risk of tissue rejection in a high-risk rabbit model, according to a
- Ellex’s Patented Glaucoma Treatment Technologies to be Spotlighted at ASCRShttps://modernod.com/news/ellexs-patented-glaucoma-treatment-technologies-to-be-spotlighted-at-ascrs/2480253/Ellex Medical Lasers Limited announced that it will showcase its proprietary glaucoma treatment portfolio, including its breakthrough iTrack minimally invasive glaucoma surgery (MIGS) technology, at the 2018 annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Wash
- Dallas Lighthouse for the Blind to Merge With Envisionhttps://modernod.com/news/dallas-lighthouse-for-the-blind-to-merge-with-envision/2480267/Envision announced that it has acquired the Dallas Lighthouse for the Blind. Operations will continue as normal in Dallas, and the Dallas Lighthouse for the Blind name will be retained. Financial terms of the deal were not disclosed. The merger will have positive benefits both in Te
- Norman Huanghttps://modernod.com/profiles/norman-huang/LAJGWW/
- FCLSA, FSLS, FBCLAhttps://modernod.com/profiles/fclsa-fsls-fbcla/j1e8xv/
- FAAOAda Noh, ODhttps://modernod.com/profiles/faaoada-noh-od/jRV15q/